We found that the expression of PAX8, a marker of ovarian cancer, was higher in cisplatin-resistant ovarian cancer organoids than those with cisplatin sensitivity, but FBP1 was opposite (Fig. 2A). Here, PAX8 is linked to ovarian cancer.